Trusted Resources: Evidence & Education
Scientific literature and patient education texts
2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
source: European Thyroid Journal
authors: Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SHsummary/abstract:
Graves’ disease (GD) is a systemic autoimmune disorder characterized by the infiltration of thyroid antigen-specific T cells into thyroid-stimulating hormone receptor (TSH-R)-expressing tissues. Stimulatory autoantibodies (Ab) in GD activate the TSH-R leading to thyroid hyperplasia and unregulated thyroid hormone production and secretion. Diagnosis of GD is straightforward in a patient with biochemically confirmed thyrotoxicosis, positive TSH-R-Ab, a hypervascular and hypoechoic thyroid gland (ultrasound), and associated orbitopathy.
In GD, measurement of TSH-R-Ab is recommended for an accurate diagnosis/differential diagnosis, prior to stopping antithyroid drug (ATD) treatment and during pregnancy. Graves’ hyperthyroidism is treated by decreasing thyroid hormone synthesis with the use of ATD, or by reducing the amount of thyroid tissue with radioactive iodine (RAI) treatment or total thyroidectomy. Patients with newly diagnosed Graves’ hyperthyroidism are usually medically treated for 12-18 months with methimazole (MMI) as the preferred drug. In children with GD, a 24- to 36-month course of MMI is recommended.
Patients with persistently high TSH-R-Ab at 12-18 months can continue MMI treatment, repeating the TSH-R-Ab measurement after an additional 12 months, or opt for therapy with RAI or thyroidectomy. Women treated with MMI should be switched to propylthiouracil when planning pregnancy and during the first trimester of pregnancy. If a patient relapses after completing a course of ATD, definitive treatment is recommended; however, continued long-term low-dose MMI can be considered. Thyroidectomy should be performed by an experienced high-volume thyroid surgeon. RAI is contraindicated in Graves’ patients with active/severe orbitopathy, and steroid prophylaxis is warranted in Graves’ patients with mild/active orbitopathy receiving RAI.organization: Johannes Gutenberg University (JGU) Medical Center, Germany; University of Insubria, Italy; Odense University Hospital, Denmark; Sorbonne University, France; Université Libre de Bruxelles (ULB),Belgium; Newcastle University, United Kingdom
read more full text
Suzanne Freitag, MDSuzanne Freitag is the Director of the O...
Breakthrough Treatment for Thyroid Eye DiseaseFor those with severe inflammation from ...
A Second Course of Antithyroid Drug Therapy for Recurrent Graves’ Disease: An Experience in Endocrine PracticeObjective: There are scarce reports reg...
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Dise...Objective: The recurrence rate associat...
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
Fatemeh Rajaii, MD, PhDFatemeh Rajaii is an Assistant Professor...
Radioactive Iodine Treatment for HyperthyroidismThe thyroid gland, located at the front ...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.